Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...